Nyxoah (NASDAQ:NYXH) versus Health Catalyst (NASDAQ:HCAT) Critical Contrast

Health Catalyst (NASDAQ:HCAT) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Institutional and Insider Ownership

85.0% of Health Catalyst shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Health Catalyst has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Earnings and Valuation

This table compares Health Catalyst and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14 million	0.52	-$177.97 million	($3.72)	-0.59
Nyxoah	$11.33 million	4.99	-$101.92 million	($2.48)	-0.59

Nyxoah has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Health Catalyst and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1	8	4	0	2.23
Nyxoah	1	1	2	0	2.25

Health Catalyst presently has a consensus target price of $2.93, indicating a potential upside of 32.66%. Nyxoah has a consensus target price of $5.96, indicating a potential upside of 308.39%. Given Nyxoah’s stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than Health Catalyst.

Profitability

This table compares Health Catalyst and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-87.69%	-3.52%	-1.77%
Nyxoah	-543.21%	-163.73%	-80.24%

About Health Catalyst

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.